# Comparative Atorvastatin Pleiotropic Effects

> **NCT00163202** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 330 (—)

## Conditions studied

- Coronary Arteriosclerosis
- Hypercholesterolemia

## Interventions

- **PROCEDURE:** Blood samples
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT00163202
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 330 (—)
- **Last updated:** 2021-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00163202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00163202, "Comparative Atorvastatin Pleiotropic Effects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00163202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*